Home/Filings/4/0000899243-19-024072
4//SEC Filing

David Nathaniel E 4

Accession 0000899243-19-024072

CIK 0001463361other

Filed

Sep 22, 8:00 PM ET

Accepted

Sep 23, 8:00 PM ET

Size

6.8 KB

Accession

0000899243-19-024072

Insider Transaction Report

Form 4
Period: 2019-09-19
David Nathaniel E
DirectorPresident
Transactions
  • Award

    Stock Option (Right to Buy)

    2019-09-19+27,82527,825 total
    Exercise: $3.43From: 2019-09-19Exp: 2027-09-25Common Stock (27,825 underlying)
Holdings
  • Common Stock, $0.0001 par value

    2,299,731
Footnotes (2)
  • [F1]Includes Restricted Stock Units which vest over time measured from the grant date.
  • [F2]On September 26, 2017, Reporting Person was granted an option exercisable for 138,417 shares. 27,118 shares vested as of December 31, 2018. Of the remaining shares, twenty-five percent (25%) was subject to vesting pursuant to the achievement of a clinical development milestone; in this case proof of concept that treatment with a senolytic drug meaningfully ameliorates a human disease. On September 19, 2019, Issuer's Board of Directors determined that such milestone was achieved.

Issuer

Unity Biotechnology, Inc.

CIK 0001463361

Entity typeother

Related Parties

1
  • filerCIK 0001559531

Filing Metadata

Form type
4
Filed
Sep 22, 8:00 PM ET
Accepted
Sep 23, 8:00 PM ET
Size
6.8 KB